GlassScriptPhysician profile
Michael J Flais
NPI 1003899808
$1,221.07
in general payments reported to CMS, 2019-2025
16 companies · $470 in 2025
The $470 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $116 · 2023: $237 · 2024: $253 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.98 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.40 | 2021-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $224.45 | 2023-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $145.19 | 2023-2025 | |
| Kaleo, INC. | $105.48 | 2022-2023 | Auvi-Q |
| Csl Behring | $84.37 | 2024-2025 | Hizentra |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $69.78 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $47.70 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $45.28 | 2024-2025 | Dupixent |
| Optinose US, INC. | $37.67 | 2021-2022 | |
| Genentech USA, INC. | $30.50 | 2025 | Xolair |
| Galderma Laboratories, L.P. | $23.46 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $18.71 | 2023 | Orladeyo |
| Pfizer INC. | $16.42 | 2023 | |
| Abbvie INC. | $12.66 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $6.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.